It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 14:41:04 Source:businessViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Here comes the char
Next:Insider Q&A: CIA's chief technologist's cautious embrace of generative AI
You may also like
- Kristin Cavallari, 37, ignores critics of her age
- China's political advisors discuss foundations of food security
- Trump to meet with Polish president Duda as NATO leaders call for additional support for Ukraine
- Mets rally in 7th and score the go
- Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
- Cowboys add veteran Royce Freeman, but running back remains a position of need in the draft
- Man gets 4 death sentences for kidnapping, rape and murder of 5
- Emma Roberts makes a splash in sexy blue swimsuit and cowboy boots
- Why US Catholics are planning pilgrimages in communities across the nation